Partnering With Cardiff Oncology

Cardiff Oncology is a clinical-stage company with the singular mission of developing onvansertib, a first-in-class, third generation Polo-like Kinase 1 (PLK1) inhibitor, to treat cancers with the greatest medical need for new therapeutic options. Our goal is to overcome resistance, improve response and increase overall survival.

For information about partnering with Cardiff Oncology, please contact us at bd@cardiffoncology.com